Rapid Appraisal System for COVID-19 Medical Information

Raymund R. Razonable; William F. Marshall; Ryan W. Stevens; Shaji Kumar; M. Hassan Murad; Walter R. Wilson

doi:10.1016/j.mayocp.2020.05.042

Rapid Appraisal System for COVID-19 Medical Information

Raymund R. Razonable, William F. Marshall, Ryan W. Stevens, Shaji Kumar, M. Hassan Murad, Walter R. Wilson

Research output: Contribution to journal › Short survey › peer-review

Original language	English (US)
Pages (from-to)	S26-S28
Journal	Mayo Clinic proceedings
Volume	95
Issue number	9
DOIs	https://doi.org/10.1016/j.mayocp.2020.05.042
State	Published - Sep 2020

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/j.mayocp.2020.05.042

Cite this

@article{18fd5a29458f4305adb201e8f8b85d81,

title = "Rapid Appraisal System for COVID-19 Medical Information",

author = "Razonable, {Raymund R.} and Marshall, {William F.} and Stevens, {Ryan W.} and Shaji Kumar and Murad, {M. Hassan} and Wilson, {Walter R.}",

note = "Funding Information: Potential Competing Interests: Dr Razonable has received research grants from Roche and Regeneron (outside the submitted work). Dr Kumar is an advisory board member of AbbVie, Celgene, Janssen, Takeda, Adaptive, KITE, MedImmune/AstraZeneca, and Oncopeptides and has received research support from AbbVie , Celgene , Janssen , Merck , Novartis , Roche , Sanofi , Takeda , KITE , and MedImmune / AstraZeneca as well as support for the independent review committee participation for Oncopeptides (all outside the submitted work). The other authors report no competing interests. Funding Information: Potential Competing Interests: Dr Razonable has received research grants from Roche and Regeneron (outside the submitted work). Dr Kumar is an advisory board member of AbbVie, Celgene, Janssen, Takeda, Adaptive, KITE, MedImmune/AstraZeneca, and Oncopeptides and has received research support from AbbVie, Celgene, Janssen, Merck, Novartis, Roche, Sanofi, Takeda, KITE, and MedImmune/AstraZeneca as well as support for the independent review committee participation for Oncopeptides (all outside the submitted work). The other authors report no competing interests.",

year = "2020",

month = sep,

doi = "10.1016/j.mayocp.2020.05.042",

language = "English (US)",

volume = "95",

pages = "S26--S28",

journal = "Mayo Clinic proceedings",

issn = "0025-6196",

publisher = "Elsevier Science",

number = "9",

}

TY - JOUR

T1 - Rapid Appraisal System for COVID-19 Medical Information

AU - Razonable, Raymund R.

AU - Marshall, William F.

AU - Stevens, Ryan W.

AU - Kumar, Shaji

AU - Murad, M. Hassan

AU - Wilson, Walter R.

N1 - Funding Information: Potential Competing Interests: Dr Razonable has received research grants from Roche and Regeneron (outside the submitted work). Dr Kumar is an advisory board member of AbbVie, Celgene, Janssen, Takeda, Adaptive, KITE, MedImmune/AstraZeneca, and Oncopeptides and has received research support from AbbVie , Celgene , Janssen , Merck , Novartis , Roche , Sanofi , Takeda , KITE , and MedImmune / AstraZeneca as well as support for the independent review committee participation for Oncopeptides (all outside the submitted work). The other authors report no competing interests. Funding Information: Potential Competing Interests: Dr Razonable has received research grants from Roche and Regeneron (outside the submitted work). Dr Kumar is an advisory board member of AbbVie, Celgene, Janssen, Takeda, Adaptive, KITE, MedImmune/AstraZeneca, and Oncopeptides and has received research support from AbbVie, Celgene, Janssen, Merck, Novartis, Roche, Sanofi, Takeda, KITE, and MedImmune/AstraZeneca as well as support for the independent review committee participation for Oncopeptides (all outside the submitted work). The other authors report no competing interests.

PY - 2020/9

Y1 - 2020/9

UR - http://www.scopus.com/inward/record.url?scp=85090719732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090719732&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2020.05.042

DO - 10.1016/j.mayocp.2020.05.042

M3 - Short survey

C2 - 32948256

AN - SCOPUS:85090719732

SN - 0025-6196

VL - 95

SP - S26-S28

JO - Mayo Clinic proceedings

JF - Mayo Clinic proceedings

IS - 9

ER -

Rapid Appraisal System for COVID-19 Medical Information

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this